Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions [Yahoo! Finance]
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Yahoo! Finance
47% of the business is held by the top 25 shareholders 37% of Contineum Therapeutics is held by Institutions Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. A look at the shareholders of Contineum Therapeutics, Inc. ( NASDAQ:CTNM ) can tell us which group is most powerful. The group holding the most number of shares in the company, around 51% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). While retail investors were the group that reaped the most benefits after last week's 10% price gain, institutions also received a 37% cut. Let's take a closer look to see what the different types of shareholders can tell us about Contineum Therapeutics. Check out our latest analysis for Contineum Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they o
Show less
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CTNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.MarketBeat
- Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CTNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CTNM&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
CTNM
Earnings
- 5/14/25 - Miss
CTNM
Sec Filings
- 2/5/26 - Form 4
- 2/3/26 - Form 144
- 1/30/26 - Form 4
- CTNM's page on the SEC website